JPM25: Bayer moves allogeneic cell therapy into phase 3 Parkinson's trial

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell therapy in the neurodegenerative disease.